Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Corrigendum to: 1757. Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to Assess Antibiotic Therapy Guided by Rapid Molecular Diagnostics (RMD) in Bloodstream Infection (BSI) Caused by Escherichia coli and Klebsiella pneumonia.

Wilson B, Viau R, Perez F, Jiang H, Fowler VG Jr, Chambers HF, Kreiswirth BN, Bonomo RA, Evans SR; ARLG.

Open Forum Infect Dis. 2019 Jul 3;6(7):ofz267. doi: 10.1093/ofid/ofz267. eCollection 2019 Jul.

2.

Sustained Circulating Bacterial Deoxyribonucleic Acid Is Associated With Complicated Staphylococcus aureus Bacteremia.

Gutierrez J, Guimaraes AO, Lewin-Koh N, Berhanu A, Xu M, Cao Y, Kim J, Yan D, Chang JK, Dinoso JB, Koss CA, Clemenzi-Allen A, Chambers HF, Peck MC, Baruch A, Rosenberger CM.

Open Forum Infect Dis. 2019 Feb 26;6(4):ofz090. doi: 10.1093/ofid/ofz090. eCollection 2019 Apr.

3.

Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.

Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00496-19. doi: 10.1128/AAC.00496-19. Print 2019 Jul.

4.

Omadacycline - The Newest Tetracycline.

Chambers HF.

N Engl J Med. 2019 Feb 7;380(6):588-589. doi: 10.1056/NEJMe1900188. No abstract available.

PMID:
30726683
5.

Clinical Practice Variation Among Adult Infectious Diseases Physicians in the Management of Staphylococcus aureus Bacteremia.

Liu C, Strnad L, Beekmann SE, Polgreen PM, Chambers HF.

Clin Infect Dis. 2019 Jan 2. doi: 10.1093/cid/ciy1144. [Epub ahead of print]

PMID:
30601989
6.

Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus.

Alexander JAN, Chatterjee SS, Hamilton SM, Eltis LD, Chambers HF, Strynadka NCJ.

J Biol Chem. 2018 Dec 21;293(51):19854-19865. doi: 10.1074/jbc.RA118.004952. Epub 2018 Oct 26.

PMID:
30366985
7.

Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2019 May 2;68(10):1691-1698. doi: 10.1093/cid/ciy766.

PMID:
30321315
8.

Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.

Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Perez F, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler VG, Chambers HF, Bonomo RA; Antibacterial Resistance Leadership Group (ARLG).

Clin Infect Dis. 2019 May 17;68(11):1823-1830. doi: 10.1093/cid/ciy801.

PMID:
30239599
9.

Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.

Holland TL, Chambers HF, Boucher HW, Corey GR, Coleman R, Castaneda-Ruiz B, Fowler VG.

Clin Infect Dis. 2019 Feb 15;68(5):865-872. doi: 10.1093/cid/ciy774.

10.

A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.

Guimaraes AO, Cao Y, Hong K, Mayba O, Peck MC, Gutierrez J, Ruffin F, Carrasco-Triguero M, Dinoso JB, Clemenzi-Allen A, Koss CA, Maskarinec SA, Chambers HF, Fowler VG, Baruch A, Rosenberger CM.

Clin Infect Dis. 2019 Apr 24;68(9):1502-1511. doi: 10.1093/cid/ciy739.

11.

PBP4: A New Perspective on Staphylococcus aureus β-Lactam Resistance.

da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS.

Microorganisms. 2018 Jun 22;6(3). pii: E57. doi: 10.3390/microorganisms6030057. Review.

12.

Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting.

Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF.

Clin Infect Dis. 2018 Sep 28;67(8):1168-1174. doi: 10.1093/cid/ciy255.

PMID:
29590355
13.

PBP4 activity and its overexpression are necessary for PBP4-mediated high-level β-lactam resistance.

Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG, Chambers HF, Chatterjee SS.

J Antimicrob Chemother. 2018 May 1;73(5):1177-1180. doi: 10.1093/jac/dkx531.

14.

A Trial of Antibiotics for Smaller Skin Abscesses.

Daum RS, Kumar N, Chambers HF.

N Engl J Med. 2017 Dec 28;377(26):e36. doi: 10.1056/NEJMc1711124. No abstract available.

PMID:
29281570
15.

Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.

Bowen AC, Carapetis JR, Currie BJ, Fowler V Jr, Chambers HF, Tong SYC.

Open Forum Infect Dis. 2017 Nov 2;4(4):ofx232. doi: 10.1093/ofid/ofx232. eCollection 2017 Fall. Review.

16.

Reply to Paul and Leibovici.

Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Ostrowsky B, Rex JH.

J Infect Dis. 2018 Jan 17;217(3):509-510. doi: 10.1093/infdis/jix537. No abstract available.

PMID:
29240925
17.

Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.

Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00452-17. doi: 10.1128/AAC.00452-17. Print 2017 Nov.

18.

PBP4 Mediates β-Lactam Resistance by Altered Function.

Chatterjee SS, Chen L, Gilbert A, da Costa TM, Nair V, Datta SK, Kreiswirth BN, Chambers HF.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00932-17. doi: 10.1128/AAC.00932-17. Print 2017 Nov.

19.

Antimicrobial Stewardship Approaches in the Intensive Care Unit.

Doernberg SB, Chambers HF.

Infect Dis Clin North Am. 2017 Sep;31(3):513-534. doi: 10.1016/j.idc.2017.05.002. Epub 2017 Jul 5. Review.

PMID:
28687210
20.

A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.

Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF; DMID 07-0051 Team.

N Engl J Med. 2017 Jun 29;376(26):2545-2555. doi: 10.1056/NEJMoa1607033.

21.

Correction for Evans et al., "Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III".

Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TTT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG Jr, Chambers HF, Bonomo RA.

J Clin Microbiol. 2017 Jun;55(6):1970. doi: 10.1128/JCM.00525-17. No abstract available.

22.

White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.

Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Newland JG, Ostrowsky B, Rex JH; Infectious Diseases Society of America.

J Infect Dis. 2017 Jul 15;216(2):228-236. doi: 10.1093/infdis/jix211. Review.

23.

High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4).

Hamilton SM, Alexander JAN, Choo EJ, Basuino L, da Costa TM, Severin A, Chung M, Aedo S, Strynadka NCJ, Tomasz A, Chatterjee SS, Chambers HF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02727-16. doi: 10.1128/AAC.02727-16. Print 2017 Jun.

24.

Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group.

Cross HR, Harris A, Arias RM, Chambers HF, Fowler VG Jr; Leadership and Operations Center; of the Antibacterial Resistance Leadership Group (ARLG).

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S8-S12. doi: 10.1093/cid/ciw825. Review.

25.

The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG Jr; Antibacterial Resistance Leadership Group (ARLG).

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824.

26.

Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.

Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01235-16. doi: 10.1128/AAC.01235-16. Print 2017 Mar.

27.

Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02243-16. doi: 10.1128/AAC.02243-16. Print 2017 Apr.

28.

Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Choo EJ, Chambers HF.

Infect Chemother. 2016 Dec;48(4):267-273. doi: 10.3947/ic.2016.48.4.267. Review.

29.

Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.

Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG Jr, Chambers HF, Bonomo RA.

J Clin Microbiol. 2016 Dec 28;55(1):134-144. doi: 10.1128/JCM.01524-16. Print 2017 Jan. Erratum in: J Clin Microbiol. 2017 Jun;55(6):1970.

30.

IVIG-mediated protection against necrotizing pneumonia caused by MRSA.

Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G.

Sci Transl Med. 2016 Sep 21;8(357):357ra124. doi: 10.1126/scitranslmed.aag1153.

PMID:
27655850
31.

Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5276-84. doi: 10.1128/AAC.00658-16. Print 2016 Sep.

32.

Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.

Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4684-9. doi: 10.1128/AAC.00243-16. Print 2016 Aug.

33.

Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.

Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3976-9. doi: 10.1128/AAC.00589-16. Print 2016 Jul.

34.

PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus.

Chan LC, Gilbert A, Basuino L, da Costa TM, Hamilton SM, Dos Santos KR, Chambers HF, Chatterjee SS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3934-41. doi: 10.1128/AAC.00358-16. Print 2016 Jul.

35.

New Societal Approaches to Empowering Antibiotic Stewardship.

Spellberg B, Srinivasan A, Chambers HF.

JAMA. 2016 Mar 22-29;315(12):1229-30. doi: 10.1001/jama.2016.1346. No abstract available.

36.

Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.

Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY.

PLoS One. 2016 Feb 18;11(2):e0149541. doi: 10.1371/journal.pone.0149541. eCollection 2016.

37.

Reply to Phillips, Morris, and Walker.

Evans S, Follmann D, Schoenfeld D, Fowler VG Jr, Chambers HF.

Clin Infect Dis. 2016 Mar 15;62(6):815-6. doi: 10.1093/cid/civ1003. Epub 2015 Dec 9. No abstract available.

38.

The 21st Century Cures Act.

Calderwood SB, Murray BE, Chambers HF.

N Engl J Med. 2015 Oct 22;373(17):1679. doi: 10.1056/NEJMc1509640. No abstract available.

PMID:
26488713
39.

Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II.

Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo AM, Fowler VG Jr, Chambers HF, Kreiswirth BN, Bonomo RA; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2016 Jan 15;62(2):181-9. doi: 10.1093/cid/civ837. Epub 2015 Sep 25.

40.

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG Jr, Lautenbach E, Chambers HF.

Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. Epub 2015 Jun 25.

41.

Antibacterial Treatment for Uncomplicated Skin Infections.

Miller LG, Daum RS, Chambers HF.

N Engl J Med. 2015 Jun 18;372(25):2460. doi: 10.1056/NEJMc1504843. No abstract available.

PMID:
26083210
42.

USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.

Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, Miller LG, Boxrud DJ, Chambers HF, Lynfield R, Lee JC, Daum RS.

MBio. 2015 Apr 7;6(2). pii: e02585-14. doi: 10.1128/mBio.02585-14.

43.

Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.

Chan LC, Basuino L, Dip EC, Chambers HF.

Antimicrob Agents Chemother. 2015;59(6):3252-6. doi: 10.1128/AAC.04376-14. Epub 2015 Mar 23.

44.

Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.

Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF; DMID 07-0051 Team.

N Engl J Med. 2015 Mar 19;372(12):1093-103. doi: 10.1056/NEJMoa1403789.

45.

Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.

Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF.

Antimicrob Agents Chemother. 2015 May;59(5):2960-3. doi: 10.1128/AAC.05004-14. Epub 2015 Mar 9.

46.

Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia.

Chambers HF.

Antimicrob Agents Chemother. 2014 Dec;58(12):7617. doi: 10.1128/AAC.03691-14. No abstract available.

47.

Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC; Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444. Erratum in: Clin Infect Dis. 2015 May 1;60(9):1448. Dosage error in article text.

PMID:
24973422
48.

Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC.

Clin Infect Dis. 2014 Jul 15;59(2):147-59. doi: 10.1093/cid/ciu296. Epub 2014 Jun 18.

PMID:
24947530
49.

Pharmacology and the treatment of complicated skin and skin-structure infections.

Chambers HF.

N Engl J Med. 2014 Jun 5;370(23):2238-9. doi: 10.1056/NEJMe1405078. No abstract available.

PMID:
24897088
50.

Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections.

David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG Jr, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, Spellberg B.

Clin Infect Dis. 2014 Sep 15;59(6):798-807. doi: 10.1093/cid/ciu410. Epub 2014 May 30.

Supplemental Content

Loading ...
Support Center